TWiV 949: Clinical update with Dr. Daniel Griffin
In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity a...
Source: virology blog - October 29, 2022 Category: Virology Authors: Vincent Racaniello Tags: This Week in Virology antiviral coronavirus COVID-19 delta inflammation influenza Long Covid marburg virus monkeypox monoclonal antibody Omicron pandemic poliovirus SARS-CoV-2 vaccine vaccine booster variant of concern Source Type: blogs

Corona second wave might bring some good news !
This article never intends to undermine the importance of preventive measures and vaccine for this worst pandemic in recent human history         (Source: Dr.S.Venkatesan MD)
Source: Dr.S.Venkatesan MD - November 17, 2020 Category: Cardiology Authors: dr s venkatesan Tags: Uncategorized corona second third wave corona second wave corona vaccine what is the case fatality rate in corona Source Type: blogs

Drugs for COVID-19: A Publishing Epidemic
As of April 9, PubMed listed 2,868 scientific publications which incorporate the word “COVID”.   323 of these (11.3%) were related to drugs under study for treatment of the disease. No fewer than thirty-one such drugs had been proposed since this pandemic first appeared on the planet four months earlier.    Graph 1 depicts the cumulative numbers of COVID-19 infection (per 100,000 global population) and introductions of relevant drugs into the Literature during February 14 to April 3. Note that both increased by a factor of approximately 16-fold during this period. In a...
Source: GIDEON blog - April 12, 2020 Category: Databases & Libraries Authors: Uri Blackman Tags: Epidemiology Graphs Source Type: blogs

Treating COVID-19 in a patient with multiple myeloma
Some readers have recently been asking me about curcumin and Covid-19. Is it good or bad to be taking it if you contract coronavirus?  Can it reduce your risk of contracting Covid-19? (See my post on vitamina D, incidentally.) I don’t know. If I had any answers, believe me, I’d be publishing them…immediately. Well, it just so happens that this afternoon I read a very interesting Science Daily article that may shed some light on this matter. It discusses the case study of ONE myeloma patient, in Wuhan, who was given an immunosuppressant drug, a monoclonal antibody, called tocilizumab. Here’s the lin...
Source: Margaret's Corner - April 4, 2020 Category: Cancer & Oncology Authors: Margaret Tags: Blogroll curcumin myeloma tocilizumab Source Type: blogs

Wim Hof Method decreases IL-6, can it prevent IL-6-induced cytokine storm in COVID19?
A subgroup of patients with severe COVID-19 may have a cytokine storm syndrome.A cytokine profile in severe COVID-19 disease includes increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-gamma inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-alpha, tumour necrosis factor-alpha, and IL-6. Mortality might be due to virally driven hyperinflammation.Anti-IL-6 antibody tocilizumab (IL-6 receptor blocker) has been used in patients with COVID-19 pneumonia and elevated IL-6. Other agents, such as sarilumab and siltuximab, which also target the IL-6 pathway...
Source: Clinical Cases and Images - Blog - April 2, 2020 Category: Universities & Medical Training Tags: COVID-19 Wim Hof Method Source Type: blogs

Chimeric Antigen Receptor Therapies Continue to Do Well Against Blood Cancers
Chimeric antigen receptor approaches to cancer treatment involve taking a patient's T cells and equipping them with a new receptor that allows the immune cells to target specific characteristics of cancer cells. Despite the usual complications and challenges that tend to occur in the development of immunotherapies, involving potentially dangerous disruption of the immune system, this type of therapy has proven to be highly effective against blood cancers. It remains to be deployed against solid cancers, although researchers are well on their way towards reaching that goal, but there is every reason to expect it to be just ...
Source: Fight Aging! - June 6, 2017 Category: Research Authors: Reason Tags: Daily News Source Type: blogs

Biologics for Takayasu Arteritis
Journal Review A multicentric retrospective analysis of 49 patients with Takayasu arteritis refractory to steroids or disease modifying drugs (mostly methotrexate and azathioprine) treated with biologics {tumor necrosis factor (TNF) alpha antagonists or tocilizumab} has been reported in Circulation [1]. Tocilizumab is a monoclonal antibody directed against interleukin 6 (IL-6). Overall response to biologics for Takayasu arteritis was 83% at one year (either partial or complete remission). The responders had a lower initial C-reactive protein levels and lower requirement for steroids. Both C-reactive protein levels and s...
Source: Cardiophile MD - November 4, 2015 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: General Cardiology Source Type: blogs

Top stories in health and medicine, January 14, 2015
From MedPage Today: Carotid Stenting Linked to High Real-World Mortality. Carotid stenting was associated with much higher than expected 2-year mortality in the Medicare population. ‘Generic’ Colchicine to Hit Market. A so-called authorized generic version of the colchicine formulation sold as Colcrys for acute gout flares and for treating familial Mediterranean fever will be “widely available” starting later this week. Newer RA Drugs Raise Serum Lipids. Rheumatoid arthritis (RA) patients treated with tofacitinib (Xeljanz) and tocilizumab (Actemra) have notable changes in serum lipids. Scant Evide...
Source: Kevin, M.D. - Medical Weblog - January 14, 2015 Category: Journals (General) Authors: Tags: News Heart Pain management Rheumatology Source Type: blogs

Top stories in health and medicine, October 30, 2014
From MedPage Today: Disease Activity Linked to Lipid Elevation in RA. Measures of disease activity at baseline and changes in those markers with tocilizumab (Actemra) treatment among patients with rheumatoid arthritis (RA) were independently associated with increased risk for major adverse cardiovascular events. Ebola: Vinson Thanks God and the Medics. Nurse Amber Vinson, thanking God and her medical team, has been released from Atlanta’s Emory University Hospital after a 14-day battle with Ebola. Healthcare Serial Killings Down in U.S. but Up Globally. The number of serial killings committed by healthcare provider...
Source: Kevin, M.D. - Medical Weblog - October 30, 2014 Category: Journals (General) Authors: Tags: News Endocrinology Heart Infectious disease Source Type: blogs

Top stories in health and medicine, June 16, 2014
From MedPage Today: The Hobby Lobby Case: The Stakes for Birth Control. One of the most watched issues before the Supreme Court this term may turn on the question of religious freedom. But it will also likely determine how women will be able to access a key provision of the Affordable Care Act — one seeking to guarantee no-cost prescription contraception in most health insurance plans. Risk Factors ID’d for Stroke Readmits. Among patients with stroke, those with a more severe event and those with more hospitalizations leading up to the stroke were most likely to be readmitted within 30 days. Combo Therapy Boo...
Source: Kevin, M.D. - Medical Weblog - June 16, 2014 Category: Journals (General) Authors: Tags: News Cancer Heart Rheumatology Source Type: blogs